SELLAS Life Sciences Group (NASDAQ:SLS) Posts Earnings Results, Beats Expectations By $0.03 EPS

SELLAS Life Sciences Group (NASDAQ:SLS) announced its quarterly earnings data on Tuesday. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.03, Zacks reports.

SELLAS Life Sciences Group Stock Performance

Shares of NASDAQ SLS traded up $0.08 during mid-day trading on Thursday, hitting $1.28. The stock had a trading volume of 1,013,920 shares, compared to its average volume of 1,277,603. SELLAS Life Sciences Group has a twelve month low of $0.50 and a twelve month high of $1.90. The firm has a market cap of $73.64 million, a PE ratio of -1.19 and a beta of 2.40. The company has a 50 day moving average of $1.21 and a two-hundred day moving average of $1.18.

Analyst Upgrades and Downgrades

Separately, Royal Bank of Canada upgraded SELLAS Life Sciences Group to a “moderate buy” rating in a report on Monday, June 24th.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.